Most public discussion drifts toward the glamorous scientific problem. Slower aging, cellular reprogramming, earlier diagnostics. Useful questions, but not the only ones. A better trail ran through enrollment criteria, employer benefits, trial participation, family offices, and the administrative machinery that decides whether a treatment counts as care or compensation.
Research Notes
If longevity medicine gets real enough to sell, access becomes the real story.
